Search research articles
Contact Us
Filters
Showing results (591-600 of 661) with videos related to
Page
of 67
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
Martin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2024
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer
James Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, et al.
JTO Clinical and Research Reports
|
June 29, 2026
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial
Nicolas Girard, Jonathan Goldman, Shun Lu, et al.
The Lancet. Oncology
|
February 28, 2025
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
Ziming Li, Yan Wang, Yuping Sun, et al.
Frontiers in Oncology
|
November 16, 2020
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable <i>KRAS</i> Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
Jonathan W Goldman, Julien Mazieres, Fabrice Barlesi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 31, 2012
Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire
David A Ostrov, Barry J Grant, Yuri A Pompeu, et al.
Journal for Immunotherapy of Cancer
|
February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Margarita Majem, Jonathan W Goldman, Thomas John, et al.
The Lancet. Oncology
|
April 17, 2016
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park, Eng-Huat Tan, Ken O'Byrne, et al.
The New England Journal of Medicine
|
September 21, 2020
Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu, Masahiro Tsuboi, Jie He, et al.
Page
of 67
Search research articles
Search
Showing results (591-600 of 661) with videos related to
Sort By:
Page
of 67
European Journal of Cancer (Oxford, England : 1990)
|
March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
Martin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2024
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer
James Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, et al.
JTO Clinical and Research Reports
|
June 29, 2026
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial
Nicolas Girard, Jonathan Goldman, Shun Lu, et al.
The Lancet. Oncology
|
February 28, 2025
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
Ziming Li, Yan Wang, Yuping Sun, et al.
Frontiers in Oncology
|
November 16, 2020
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable <i>KRAS</i> Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
Jonathan W Goldman, Julien Mazieres, Fabrice Barlesi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 31, 2012
Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire
David A Ostrov, Barry J Grant, Yuri A Pompeu, et al.
Journal for Immunotherapy of Cancer
|
February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Margarita Majem, Jonathan W Goldman, Thomas John, et al.
The Lancet. Oncology
|
April 17, 2016
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park, Eng-Huat Tan, Ken O'Byrne, et al.
The New England Journal of Medicine
|
September 21, 2020
Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu, Masahiro Tsuboi, Jie He, et al.
Page
of 67